8-K/A: Alaunos Therapeutics Implements 1-for-10 Reverse Stock Split

Alaunos Therapeutics has completed a 1-for-10 reverse stock split, effective July 17, 2024, to increase its share price and maintain Nasdaq listing compliance.

Summary

• Alaunos Therapeutics has enacted a 1-for-10 reverse stock split of its common stock.
• The reverse stock split was approved by the board on June 26, 2024, and will be effective on July 17, 2024, at 5:00 p.m. Eastern Time.
• Every 10 shares of existing common stock will be combined into 1 share.
• The company's stock will continue to trade on the Nasdaq under the symbol TCRT, but with a new CUSIP number (98973P309) starting July 18, 2024.
• The reverse stock split was authorized by stockholders at the annual meeting on June 6, 2024, with the board having discretion to set the ratio between 1-for-5 and 1-for-15.
• Equiniti Trust Company is the exchange agent and will provide instructions to stockholders on exchanging pre-split shares for post-split shares.
• No fractional shares will be issued; instead, shareholders will receive cash based on the closing price of the stock on the day before the effective time.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment, detailing a necessary corporate action to maintain listing compliance. While not inherently positive, it is a standard procedure.

Positives

• The reverse stock split is a step to maintain Nasdaq listing compliance.
• The board had the flexibility to choose the ratio within a range approved by shareholders.
• Shareholders will receive cash for fractional shares, avoiding complications.

Risks

• Reverse stock splits can sometimes be perceived negatively by the market.
• The company's stock price may be volatile following the reverse split.

Future Outlook

The company's common stock will trade on a split-adjusted basis starting July 18, 2024, under the same ticker symbol but with a new CUSIP number.

Management Comments

• The Board of Directors approved the reverse stock split and the 1-for-10 ratio.
• The Interim Chief Executive Officer signed the Third Amended and Restated Certificate of Incorporation.

Industry Context

Reverse stock splits are a common corporate action for companies seeking to maintain listing compliance on exchanges like Nasdaq, often used when a stock price falls below minimum thresholds.

Comparison to Industry Standards

• Reverse stock splits are a standard mechanism used by companies to increase their share price and avoid delisting.
• The 1-for-10 ratio is within the typical range for reverse stock splits, which can vary widely depending on the company's specific situation.
• Other companies facing similar listing compliance issues have used reverse stock splits, such as Cassava Sciences (SAVA) which had a 1-for-5 split in 2023, and Ocugen (OCGN) which had a 1-for-10 split in 2024.

Stakeholder Impact

• Shareholders will have fewer shares but at a higher price per share.
• Shareholders will receive cash in lieu of fractional shares.
• The company aims to maintain its Nasdaq listing, which is important for investor confidence.

Next Steps

• Stockholders will receive instructions from Equiniti Trust Company on how to exchange their pre-split shares for post-split shares.
• The company's stock will begin trading on a split-adjusted basis on July 18, 2024.

Key Dates

Keywords

reverse stock split, common stock, Nasdaq, TCRT, shareholders, corporate action, stock split, equity